Clinical Trials
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
Pfizer Inc. and BioNTech SE announced that two of the companies’ four investigational vaccine candidates from their BNT162 mRNA-based vaccine program (BNT162b1 and BNT162b2) being...
Clinical Trials
QUT and Oxford collaborate on clinical trial to test asthma inhalers as treatment for COVID-19
QUT researchers are collaborating with colleagues at the University of Oxford on a UK clinical trial to test common asthma inhalers as a treatment for...
Clinical Trials
Zydus vaccine for COVID-19 (ZyCoV-D) successfully completes preclinical development and receives permission to initiate human clinical trials
Zydus an innovation-driven, global pharmaceutical company, announced that it's plasmid DNA vaccine candidate for COVID-19 (ZyCoV-D) developed indigenously at its Vaccine Technology Centre in Ahmedabad,...
Clinical Trials
ERT Continues to Drive Innovation in Virtualization for Respiratory Clinical Trials
ERT, the global leader in clinical endpoints data collection, announced a strategic partnership with Inofab Health, a healthcare technology company designing and developing ultrasonic spirometry...
Clinical Trials
Avalon GloboCare Announces Successful Completion of Phase I Clinical Study of CAR T-Cell Therapy Candidate AVA-001
Avalon GloboCare Corp., a clinical-stage global developer of cell-based technologies and therapeutics, announced it has successfully completed Phase I first-in-human clinical study of its leading...
Clinical Trials
Samsung Bioepis Initiates Phase 3 Clinical Trial for SB15, Proposed Biosimilar to Eylea
Samsung Bioepis announced the initiation of Phase 3 clinical trial for SB15, the company's proposed biosimilar referencing Eylea® (aflibercept). The Phase 3 clinical trial for...
Clinical Trials
Astrazeneca: Selumetinib granted orphan drug designation in Japan for neurofibromatosis type 1
AstraZeneca announced that selumetinib has been granted orphan drug designation (ODD) in Japan for the treatment of neurofibromatosis type 1 (NF1), a rare and debilitating...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.